Dr. Saad Z. Usmani on Carfilzomib and Filanesib in Multiple Myeloma

Publication
Video
Special ReportsHematologic Malignancies: Multiple Myeloma
Volume 2
Issue 2

Saad Z. Usmani, MD, discusses the combination of carfilzomib and filanesib as a treatment for multiple myeloma.

Saad Z. Usmani, MD, director, Plasma Cells Disorder Program, Levine Cancer Institute/Carolinas Healthcare System, discusses the combination of carfilzomib and filanesib as a treatment for multiple myeloma. Usmani said a recent phase II study showcased a response rate of 14% in the carfilzomib-only arm, while a response rate of 35% was seen in the arm with patients receiving a combination of carfilzomib and filanesib.

Usmani said the regimen was efficacious, though the main question still persisting post study is how much dosing of carfilzomib should be included in an upcoming phase III study.

Recent Videos
1 expert in this video
1 expert in this video
4 experts are featured in this series.
1 expert in this video
1 expert in this video
Related Content